Replies to post #104584 on Biotech Values

[DewDiligence]

The squamous won't kill them.

But see ifwal’s concern in #msg-53783981, which has not to my knowledge been dismissed.

[jq1234]

What's more interesting to me is what drugs will be combined with PLX to extend the impressive but still relatively modest duration.

I heard discussion between Roche and BMY to combine PLX with Ipi.

[genisi]

What's more interesting to me is what drugs will be combined with PLX to extend the impressive but still relatively modest duration.

And resistance (in addition to limited duration). GSK is running a combo trial of BRAF + MEK Inhibitors in melanoma to eliminate resistance.

http://clinicaltrials.gov/ct2/show/NCT01072175?term=GSK2118436++GSK1120212&rank=1